Search
Omeros Corp
OMERAdd to Watchlist
9.280USD
-0.130-1.38%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
538.83MMarket Cap
7.12P/E TTM
More Details of Omeros Corp Company
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Omeros Corp Info
Ticker SymbolOMER
Company nameOmeros Corp
IPO dateOct 08, 2009
CEODemopulos (Gregory A)
Number of employees202
Security typeOrdinary Share
Fiscal year-endOct 08
Address201 Elliott Avenue West
CitySEATTLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code98119
Phone12066765000
Websitehttps://www.omeros.com/
Ticker SymbolOMER
IPO dateOct 08, 2009
CEODemopulos (Gregory A)
Company Executives of Omeros Corp
Name
Name/Position
Position
Shareholding
Change
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
972.90K
+61.67%
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Rajiv Shah, M.D.
Dr. Rajiv Shah, M.D.
Independent Director
Independent Director
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. George A. Gaitanaris, M.D., Ph.D.
Dr. George A. Gaitanaris, M.D., Ph.D.
Vice President - Science, Chief Scientific Officer
Vice President - Science, Chief Scientific Officer
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
Dr. J. Steven Whitaker, M.D., J.D.
Dr. J. Steven Whitaker, M.D., J.D.
Vice President - Clinical Development
Vice President - Clinical Development
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
972.90K
+61.67%
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Rajiv Shah, M.D.
Dr. Rajiv Shah, M.D.
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Omeros Corp?
The top five shareholders of Omeros Corp are: Dr. Peter A. Demopulos, M.D.
How many institutions hold shares of Omeros Corp (OMER)?
As of 2026Q1, 290 institutions hold shares of Omeros Corp, with a combined market value of approximately 38.03M, accounting for 52.70% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1795629.00.